Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Arcellx Inc
ACLXArcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. Address: 800 Bridge Parkway, Redwood City, CA, United States, 94065
Analytics
Preço Alvo de Wall Street
105.44 USDRácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave ACLX
Análise de Dividendos ACLX
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Histórico de Dividendos ACLX
Avaliação de ações ACLX
Relatório ACLX
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |